Skip to main content

Table 1 Baseline characteristics of MC-CAP and SP-CAP patients

From: Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults: a retrospective single-centre study

  MC-CAP (%) SP-CAP (%) P valuea
Number of patients 134 130  
Background
 Age: mean ± SD 75.2 ± 15.6 66.2 ± 17.4 < 0.01
 Gender (M/F) 72/62 64/66 0.46
 Body mass indexb, mean ± SD 23.6 ± 5.6 22.4 ± 3.5 < 0.05
 Ever smoker 55 (41) 42 (32.3) 0.14
Underlying pulmonary disease
 Asthma 51 (38.1) 25 (19.2) < 0.01
 Bronchiectasis 56 (41.8) 22 (16.9) < 0.01
 Chronic obstructive pulmonary disease (COPD) 35 (26.1) 26 (20) 0.24
 Interstitial pneumonia 6 (4.5) 1 (0.8) 0.06
 Lung cancer 6 (4.5) 4 (3.1) 0.55
 Old tuberculosis 15 (11.2) 10 (7.7) 0.33
 Under home oxygen therapy 16 (11.9) 4 (3.1) < 0.01
 Usage continuous positive airway pressure therapy 6 (4.5) 1 (0.8) 0.06
Systemic underlying disease
 Cerebrovascular disease 7 (5.2) 4 (3.1) 0.38
 Chronic heart failure 41 (30.6) 18 (13.8) < 0.01
 Chronic kidney disease 15 (11.2) 3 (2.3) < 0.01
 Collagen disease 3 (2.2) 0 (0) 0.08
 Diabetes mellitus 23 (17.2) 14 (10.8) 0.13
 Hypertension 64 (47.8) 48 (36.9) 0.07
 Malignancy 15 (11.2) 8 (6.2) 0.14
Severity
 CURB-65
  Mild 96 (71.6) 103 (79.2) 0.15
  Moderate 32 (23.9) 22 (16.9) 0.16
  Severe 6 (4.5) 5 (3.8) 0.79
 qSOFA
   ≥ 2 5 (3.7) 8 (6.2) 0.36
Clinical manifestation
 High fever (≥38 °C) 50 (37.3) 80 (61.5) < 0.01
 Systolic blood pressure ≤ 100 mmHg 3 (2.2) 11 (8.5) < 0.05
 Shaking chill 8 (6) 26 (20) < 0.01
 COPD exacerbation 10/35 (28.6) 5/26 (19.2) 0.4
 Asthma attack 24/51 (47) 13/25 (52) 0.68
Laboratory data
 White blood cellc, mean ± SD 11,451 ± 4556 12,543 ± 5118 < 0.05
 C-reactive proteind, mean ± SD 8.2 ± 7.4 9.1 ± 7.6 0.17
 Serum albumine, mean ± SD 3.6 ± 0.5 3.7 ± 0.5 0.21
 Positive for influenza virus rapid test 4 (3) 19 (14.6) < 0.01
Blood culture
 Positive 1 (0.7) 2 (1.5) 0.54
Initial treatment
 Penicillin (ABPC, ABPC/SBT, AMPC, or AMPC/CVA) 70 (52.2) 71 (54.6) 0.69
 Cephalosporin (CTM, CTRX, CTX, or CMZ) 48 (35.8) 51 (39.2) 0.57
 Macrolides (AZM) 8 (6) 6 (4.6) 0.62
 Tetracyclines (MINO) 5 (3.7) 0 (0) < 0.05
 Fluoroquinolones (LVFX) 2 (1.5) 1 (0.8) 0.57
Outcome
 Hospitalised patients 79 (59) 76 (58.4) 0.93
 Length of antibiotic treatment, mean ± SD 6.8 ± 2.2 7.1 ± 2.3 0.17
 Length of hospital stay, mean ± SD 9.2 ± 4.7 8.6 ± 3.0 0.19
 In-hospital mortality 0 0
  1. Abbreviations: COPD chronic obstructive pulmonary disease, SD standard deviation, ABPC ampicillin, ABPC/SBT ampicillin sulbactam, AMPC amoxicillin, AMPC/CVA amoxicillin clavulanate, CTM cefotiam, CTRX ceftriaxone, CTX cefotaxime, CMZ cefmetazole, AZM azithromycin, MINO minocycline, LVFX levofloxacin
  2. aStatistical differences between MC-CAP and SP-CAP were evaluated by Pearson’s χ2 or Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous variables
  3. bNumber of patients was 108 in MC-CAP and 93 in SP-CAP
  4. cNumber of patients was 118 in MC-CAP and 113 in SP-CAP
  5. dNumber of patients was 117 in MC-CAP and 109 in SP-CAP
  6. eNumber of patients was 98 in MC-CAP and 91 in SP-CAP